News & Articles

FEATURED ARTICLE

MASP2 Antibody Successful in Phase III Clinical Trial

On December 19, 2024, Omeros announced that its pivotal Phase 3 clinical trial of the MASP2 antibody Narsoplimab (OMS721) in the treatment of TA-TMA (Transplant-Associated Thrombotic Microangiopathy) met its primary endpoint of overall survival (OS), with a 3-fold reduction in mortality risk [1]. Omeros stock surged 37% after the press release...

Read more

Browse articles by topic:

Immunotherapy Target: CD19 Antigen

Immunotherapy Target: CD19 Antigen

February 4, 2025

7 min read

CD19 remains a hot target in immunotherapy, driving innovation across a range of diseases. This is evidenced by recent approvals...

Read more →
NK Cell Therapy Gets IND FDA Clearance with AccuBase® Base Editor from KACTUS

NK Cell Therapy Gets IND FDA Clearance with AccuBase® Base Editor from KACTUS

November 21, 2024

5 min read

November 14, 2024 Base Therapeutics announced that its independently developed NK510 cell injection, the world's first base-edited universal NK cell...

Read more →
Cell and Antibody Therapies Targeting HLA-G

Cell and Antibody Therapies Targeting HLA-G

February 14, 2023

3 min read

On December 19, 2022, the FDA approved the Phase I/IIa clinical trial application of IVS-3001, an anti-HLA-G Chimeric Antigen Receptor-T...

Read more →
TCR Therapy Targeting MAGE-A4

TCR Therapy Targeting MAGE-A4

January 2, 2023

1 min read

Recently at the 2022 CTOS Conference, Adaptimmune announced the SPEARHEAD-1 clinical trial data of its T cell receptor-engineered T cell...

Read more →
CDH17: A Safe CAR-T Target for Treatment of Solid Tumors

CDH17: A Safe CAR-T Target for Treatment of Solid Tumors

July 19, 2022

5 min read

Chimeric antigen receptor T cell (CAR-T) therapy has been successful in the field of hematological malignancies, but it is not...

Read more →

Have questions? Get in touch!

support@kactusbio.us

Contact Us